Osteopontin, Malondialdehyde and Interleukin-1b levels in patients with insulin resistance and dyslipidemia in obese Egyptian women

Abstract

Osteopontin (OPN) is a pro-inflammatory cytokine implicated in immune processes regulation and mediating chronic inflammation. Interleukin-1b (IL-1b) is the key mediator of the inflammatory response and malondialdehyde (MDA) reflects oxidative stress status. Dyslipidemia may contribute to the increase in serum MDA. Chronic inflammation plays a principal role in the development of insulin resistance (IR). Our goal was to investigate the correlation between circulating OPN, IL-1b and MDA in obese women with IR and dyslipidemia subgroup. This interaction has not yet been studied in Egyptian obese subjects. The study included 200 obese women with IR and100 healthy controls. Patients with IR were divided into two subgroups according to presence of dyslipidemia. OPN and IL-1b were measured using an enzyme-linked immunosorbent commercial assay. MDA was assessed spectrophotmetrically. The anthropometric measurements were assessed for each participant. OPN, total cholesterol, LDL-C, fasting glucose, MDA and IL-1b were significantly increased in obese women with IR in comparison with control group. The dyslipidemic group presented significant higher levels of serum lipids, OPN MDA and waist circumference compared to the non-dyslipidemic group. This study highlights the increase of serum OPN, MDA and IL-1b levels in obese cases with IR. OPN might be important biomarker for IR and for the early diagnosis of dyslipidemia in IR patients. Therefore, the pharmacological inhibition of OPN levels might be a novel approach for the treatment of these cases.